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To determine the frequency of breast cancer (BC) patients with hereditary risk features in a
wide retrospective cohort of patients in Spain.
Methods
a retrospective analysis was conducted from 10,638 BC patients diagnosed between 1998
and 2001 in the GEICAM registry “El Álamo III”, dividing them into four groups according to
modified ESMO and SEOM hereditary cancer risk criteria: Sporadic breast cancer group
(R0); Individual risk group (IR); Familial risk group (FR); Individual and familial risk group
(IFR) with both individual and familial risk criteria.
Results
7,641 patients were evaluable. Of them, 2,252 patients (29.5%) had at least one hereditary
risk criteria, being subclassified in: FR 1.105 (14.5%), IR 970 (12.7%), IFR 177 (2.3%).
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There was a higher frequency of newly diagnosed metastatic patients in the IR group (5.1%
vs 3.2%, p = 0.02). In contrast, in RO were lower proportion of big tumors (> T2) (43.8% vs
47.4%, p = 0.023), nodal involvement (43.4% vs 48.1%, p = 0.004) and lower histological
grades (20.9% G3 for the R0 vs 29.8%) when compared to patients with any risk criteria.
Conclusions
Almost three out of ten BC patients have at least one hereditary risk cancer feature that
would warrant further genetic counseling. Patients with hereditary cancer risk seems to be
diagnosed with worse prognosis factors.
Introduction
Breast cancer is the most frequent malignancy in women [1]. In Spain, it is estimated an age-
standardized (European standard population) incidence of 85 cases per 100,000 women [2],
that would be translated in 25,200 new cases per year. Breast cancer deaths are estimated to be
18% of cancer mortality [3]. Known risk factors are age, late and non-parity, post-menopausal
status, and familial background. Preventive and early diagnostic strategies are necessary to
reduce the disease burden. However, these strategies vary among countries and even within
regions of the same country [4], while there is an increasing interest in adapting screening
strategies to the basal breast cancer risk [5]. In this sense, identifying high-risk groups in terms
of frequency and prognosis is mandatory for a rationale preventive approach.
It is widely described in the literature that up to 25% of breast cancer patients have a famil-
ial/hereditary background, that can be explained through a genetic condition only in a small
percentage [6]. Population studies that support this data are scarce, and whether these patients
have different prognostic factors or not is a term of debate. Identification of patients at risk of
hereditary breast cancer is especially important for those cases that harbor pathological genetic
germline mutations in BRCA1 or 2.
Recently, the Spanish Medical Oncology Society (SEOM) have suggested clinical criteria for
genetic test selection of hereditary breast cancer patients through a clinical guideline [7]. In
the European context, the European Society for Medical Oncology (ESMO) has its own guide-
lines [6]. In the North American context, the criteria seem to be less restrictive [8].
The implications of genetic testing are nowadays going beyond the prevention and early
detection area, influencing also therapeutic decisions with the use of specific treatments, such
as oral PARP inhibitors or platinum-based regimens. Currently, several clinical trials are ongo-
ing for different clinical scenarios with these treatments, from the metastatic disease to the
adjuvant setting, being in the spotlight of the oncology breast cancer community [9].
In summary, a better understanding of the epidemiological landscape of breast cancer
patients with hereditary risk features is of interest.
El Álamo Project is a retrospective observational study that includes 26,658 breast cancer
patients diagnosed between 1990 and 2001 across 43 Spanish Hospitals and distributed in
three cohorts: El Alamo I with 4,532 patients diagnosed between 1990 and 1993, El Alamo II
with 10,849 patients diagnosed between 1994 and 1997 and El Alamo III with 11,277 patients
diagnosed between 1998 and 2001. El Alamo project has the aim to describe patterns of pre-
sentation, management and outcomes of breast cancer in Spain [10, 11]. The latest version, El
Álamo III, included for the first time the familial background of patients, in addition to clinical
and personal features linked to hereditary risk (i.e age, bilaterality, triple negative histology).
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With more than eleven thousand invasive breast cancer patients diagnosed in 11 of the 17
Spanish regions [12], this is an unique opportunity to explore the previously mentioned ques-
tions regarding hereditary breast cancer epidemiology in Spain, since no studies of this kind
are currently available in the European context.
The objectives of this study are to analyze the frequency and clinical/pathological character-
istics of Spanish invasive breast cancer patients with hereditary risk features.
Patients and methods
Compliance with ethical standards
All procedures performed in this study were in accordance with the ethical standards of the
participant institutions and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. “Comité Etico de Investigación Clı́nica del Area 1” IRB reviewed
and approved the Alamo project.
Study design
This is a retrospective analysis from El Álamo III project that included 11,277 breast cancer
patients. El Alamo focused on female breast cancer and only some centers recruited a small
number of male patients (37 cases, 0.3% of the total sample), so they were excluded from this
analysis. Non invasive carcinoma breast cancer cases (602 patients, 5.3%) were also excluded.
Questionnaires including data regarding individual tumor information and familial fea-
tures were completed by the clinical investigators (it can be found in reference [12]. Based on
these data, hereditary risk groups were defined, according to the following modified SEOM
and ESMO criteria [6, 7].
Modified ESMO-SEOM Criteria for hereditary breast cancer risk
The individual criteria were: breast cancer diagnosis under 40 years or breast cancer diagnosis
under 50 years if one of the following: triple negative breast cancer (TNBC) histology and/or
bilateral (synchronous or metachronous) breast cancer or breast cancer at any age together
with ovarian cancer. The familial criteria were: the presence of first or second degree relatives
with the following features: 3 relatives (including the patient) with breast and /or ovarian can-
cer or 2 relatives (including the patient), if the relative fulfill any of the individual criteria
above mentioned, regardless degree; or 2 relatives (including the patient) if is first degree and
diagnosed with breast and/or ovarian cancer.
According to the individual and familial criteria, patients were divided into 4 different sub-
groups: Sporadic breast cancer group (R0) (Control group) without individual or familial risk
criteria; Individual risk group (IR) with no familial or not determined (ND) familial risk, but
with individual risk criteria; Familial risk group (FR) with no individual or ND individual risk,
but with familial risk criteria; Individual and familial risk group (IFR) with both individual and
familial risk criteria. Global hereditary risk group (GHR) comprises the three last categories,
namely IR or FR or IFR.
Statistical methods
Chi-square and unpaired t student/Anova were used to compare categorical and continuous
variables respectively. All statistical tests had a significance level of 0.05 unless stated otherwise.
Data were analysed using SPSS1 version 21 (IBM corporation).
Familial breast cancer in Spain
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Results
Frequency and characteristics of hereditary risk breast cancer patients
From 1998 to 2001, 10,638 women with invasive breast cancer were included in the study.
Patients who had enough information to be sub-classified as one of the four risk subgroups
accounted for 7,641 (71.8%). The individual and familial risk criteria for hereditary breast can-
cer of the global sample are described in Table 1. Eleven out of the 17 different Spanish regions
were represented (64.7%).
Of these evaluable patients, 2,252 patients (29.5%) had at least one hereditary risk criteria,
constituting the global hereditary risk group (GHR). The 5,389 (70.5%) remaining patients,
with no risk features, were considered the R0 group (Table 2). Table 3 describes the pathologi-
cal characteristics of patients evaluable for hereditary risk (N = 7,641).
Analysis of prognostic factors in sporadic and hereditary breast cancer
groups
In the univariate analysis we found that R0 group presented a lower proportion of big tumors
( T2) than the GHR group (43.8% vs 47.4%, p = 0.023), a lower proportion of nodal
Table 1. Individual and familial features distribution in the global sample.
Individual risk features: 1902 patients (17,9%) had not information
N %
Age < 40 ya 973 11,1
> = 40 y & <50y & TNBC 122 1,4
> = 40 y & <50y & Bilateral 19 0,2
Ovarian cancer 33 0,4
Non personal risk features 7589 86,9
Total 8736 100,0
Familial background features: 1944 patients (18,3%) had not information
N %
2 relatives (patient + relative with ovarian cancer) 111 1,3
3 or more relatives (patient + 2 relatives with BC and/or ovarian cancer, regardless degree) 434 5,0
2 relatives (patient + 1 BC of first degree) 737 8,5
No family featuresb 7412 85,2
Total 8694 100,0
a 67 patients were also TNBC; 6 were also bilateral BC; 4 had also ovarian cancer; 1 was TNBC and bilateral
BC;
b528 of them had 1 relative but in second degree with BC, not considered in consequence at hereditary risk
https://doi.org/10.1371/journal.pone.0184181.t001
Table 2. Hereditary risk distribution.
2533 patients (23,8%) had some feature missing Excluding those without information
N %
R0 (Sporadic) 5389 70,5
IFR (both individual and familial) 177 2,3
IR (only individual risk) 970 12,7
FR (only familial risk) 1105 14,5
Total 7641 100,0
https://doi.org/10.1371/journal.pone.0184181.t002
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involvement (43.4% vs 48.1%, p = 0.004) and lower histological grades (20.9% G3 for the R0 vs
29.8% for the GHR group, p<0.001). Metastases at diagnosis were present in similar propor-
tion in both groups (3.2% vs 3.9%, p = 0.26). As expected, a higher proportion of TNBC was
found in the GHR group, given that the TN phenotype is included in the criteria to define
hereditary cancer (Table 3). In order to rule out an effect by TN phenotype itself in this obser-
vation, we conducted the same analysis excluding from all subgroups the TN patients
(Table 4), and we found that RO maintained a statistically significant lower proportion of
nodal involvement (43.6% vs 48.7%, p = 0.00173) and lower histological grades (19.4% G3 for
the R0 vs 26.8% for the GHR group, p<0.001). However, tumor size was not statistically signif-
icant between the two subgroups (Table 4)
Analysis according to different hereditary risk subgroups
Comparing each specific GHR subtype with sporadic cases, we observed that the differences
seen before are only observed for the IR group. In contrast, similar clinic-pathological features
were seen between R0 and IFR and FR groups respectively (Table 3). Moreover, there was a
higher frequency of newly diagnosed metastatic patients in the IR group (5.1% vs 3.2%,
p = 0.02)
Table 3. Description of the TNM, histological subtype and grade of the evaluable patients, including TN patients. Only pathological T and N were
considered.
R0 GHR (IFR+IR+FR) p-value IFR IR FR p-value
N (%) N (%) N (%) N (%) N (%)
pT (N = 6746) N = 4813 N = 1933 0.023 (T0+T1 vs T2+T3+T4) N = 153 N = 804 N = 976 <0.001 (T0+T1 vs T2+T3+T4)
T0 (Tis) 10 (0.2) 9 (0.5) 0 2 (0.2) 7 (0.7)
T1 (52 T1mic) 2703 (56.2) 1017 (52.6) 87 (56.8) 365 (45.5) 565 (57.9)
T2 1738 (36.1) 752 (38.9) 57 (37.3) 361 (44.9) 334 (34.2)
T3 164 (3.4) 74 (3.8) 6 (3.9) 46 (5.7) 22 (2.3)
T4 180 (3.7) 65 (3.4) 2 (1.3) 21 (2.6) 42 (4.3)
TX 18 (0.4) 16 (0.8) 1 (0.7) 9 (1.1) 6 (0.6)
pN (N = 6746) N = 4813 N = 1933 0.004 (NX not analysed) N = 153 N = 804 N = 976 <0.001 (NX not analysed)
N0 2721 (56.6) 1003 (51.9) 84 (54.9) 385 (47.9) 534 (54.7)
N1 1671 (34.7) 748 (38.7) 55 (35.9) 347 (43.2) 346 (35.5)
N2 243 (5.0) 112 (5.8) 7 (4.6) 55 (6.8) 50 (5.1)
N3 76 (1.6) 28 (1.4) 5 (3.3) 9 (1.1) 14 (1.4)
NX 102 (2.1) 42 (2.2) 2 (1.3) 8 (1.0) 32 (3.3)
M (N = 7641) N = 5389 N = 2252 0.256 (M ND not analysed) N = 177 N = 970 N = 1105 0.02 (M ND not analysed)
M0 5219 (96.8) 2165 (96.1) 172 (97.2) 920 (94.9) 1073 (97.1)
M1 167 (3.1) 81 (3.6) 5 (2.8) 47 (4.8) 29 (2.6)
M ND 3 (0.1) 6 (0.3) 0 3 (0.3) 3 (0.3)
Grade H (N = 7641) N = 5389 N = 2252 <0.001 (GX not analysed) N = 177 N = 970 N = 1105 <0.001 (GX not analysed)
GX 947 (17.6) 429 (19.0) 30 (16.9) 188 (19.4) 211 (19.1)
G1 1140 (21.2) 335 (14.9) 21 (11.9) 97 (10.0) 217 (19.6)
G2 2177 (40.3) 817 (36.3) 54 (30.5) 349 (36.0) 414 (37.5)
G3 1125 (20.9) 671 (29.8) 72 (40.7) 336 (34.6) 263 (23.8)
Subtypes (N = 7641) N = 5389 N = 2252 <0.001(unknown not analysed) N = 177 N = 970 N = 1105 <0.001 (unknown not analysed)
TN 208 (3.9) 225 (10.0) 33 (18.6) 159 (16.4) 33 (3.0)
Her2+ 552 (10.2) 224 (9.9) 15 (8.5) 124 (12.8) 85 (7.7)
RH+ Her2- 1452 (26.9) 499 (22.2) 36 (20.3) 200 (20.6) 263 (23.8)
Unknown 3177 (59.0) 1304 (57.9) 93 (52.6) 487 (50.2) 724 (65.5)
https://doi.org/10.1371/journal.pone.0184181.t003
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Discussion
According to this large and representative sample of the Spanish breast cancer landscape, we
can say that three out of ten patients have, at least, one hereditary breast cancer risk feature,
and, in consequence, could be candidate for genetic testing and counselling. Overall, patients
with hereditary cancer risk features have larger tumors and more frequently nodal involve-
ment in comparison to patients without hereditary cancer risk features, while both subgroups
have a similar rate of distant metastases at initial diagnosis. However, these differences proba-
bly are related to the greater aggressiveness observed in patients fulfilling the individual crite-
ria. Interestingly, when patients with TNBC were excluded for this analysis, presence of nodal
involvement and higher grades, although not tumor size, remained higher in patients with
hereditary risk features.
Strong points of this study are the large number of patients analyzed and the representative-
ness’ of Spanish population, since two thirds of the regions are represented. Few studies exist
in Spain analyzing the frequency of different familial cancer from a population point of view,
with the exception of melanoma [13], pancreatic [14] and colorectal cancer [15]. However,
several limitations must be also taken into account when interpreting our results. First, the ret-
rospective nature of our work that could concur in some bias, since almost 30% of patients
analyzed lack information to be included in a given risk group. Based on that, we decided to
analyze only those that could be categorized in a risk group. This could be a selection bias,
Table 4. Description of the TNM, histological subtype and grade of the evaluable patients, excluding those TN patients. Only pathological T and N
were considered.
R0 GHR (IFR+IR+FR) p-value IFR IR FR p-value
N (%) N (%) 0.061 (T0+T1 vs T2+T3+T4) N (%) N (%) N (%)
pT (N = 6382) N = 4637 N = 1745 N = 125 N = 672 N = 948 0.146 (T0+T1 vs T2+T3+T4)
T0 (Tis) 10 (0.2) 9 (0.5) 0 2 (0.3) 7 (0.7)
T1 (49 T1mic) 2634 (56.8) 936 (53.6) 68 (54.4) 309 (46.0) 559 (59.0)
T2 1640 (35.4) 658 (37.7) 48 (38.4) 292 (43.4) 318 (33.6)
T3 158 (3.4) 66 (3.8) 6 (4.8) 40 (6.0) 20 (2.1)
T4 177 (3.8) 61 (3.5) 2 (1.6) 20 (3.0) 39 (4.1)
TX 18 (0.4) 15 (0.9) 1 (0.8) 9 (1.3) 5 (0.5)
pN (N = 6382) N = 4637 N = 1745 0.00173 (NX not anlysed) N = 125 N = 672 N = 948 0.001 (NX not anlysed)
N0 2614 (56.4) 896 (51.3) 67 (53.6) 307 (45.7) 522 (55.0)
N1 1617 (34.9) 678 (38.9) 46 (36.8) 299 (44.5) 333 (35.1)
N2 229 (4.9) 106 (6.1) 6 (4.8) 51 (7.6) 49 (5.2)
N3 76 (1.6) 24 (1.4) 4 (3.2) 7 (1.0) 13 (1.4)
NX 101 (2.2) 41 (2.3) 2 (1.6) 8 (1.2) 31 (3.3)
M (N = 7208) N = 5181 N = 2027 0.1139 (M ND not analysed) N = 144 N = 811 N = 1072 0.01383 (M ND not analysed)
M0 5020 (96.9) 1945 (96.0) 139 (96.5) 766 (94.5) 1040 (97.0)
M1 159 (3.1) 77 (3.8) 5 (3.5) 43 (5.3) 29 (2.7)
M ND 2 (0.0) 5 (0.2) 0 2 (0.2) 3 (0.3)
Grade H (N = 7208) N = 5181 N = 2027 <0.001 (GX not analysed) N = 144 N = 811 N = 1072 <0.001 (GX not analysed)
GX 912 (17.6) 399 (19.7) 26 (18.1) 168 (20.7) 205 (19.1)
G1 1128 (21.8) 324 (16.0) 19 (13.2) 88 (10.9) 217 (20.2)
G2 2134 (41.2) 760 (37.5) 49 (34.0) 303 (37.3) 408 (38.1)
G3 1007 (19.4) 544 (26.8) 50 (34.7) 252 (31.1) 242 (22.6)
Subtypes (N = 7208) N = 5181 N = 2027 0.079 (unknown not analysed) N = 144 N = 811 N = 1072 <0.001 (unknown not analysed)
Her2+ 552 (10.7) 224 (11.1) 15 (10.4) 124 (15.3) 85 (7.9)
RH+ Her2- 1452 (28.0) 499 (24.6) 36 (25.0) 200 (24.7) 263 (24.5)
Unknown 3177 (61.3) 1304 (64.3) 93 (64.6) 487 (60.0) 724 (67.6)
https://doi.org/10.1371/journal.pone.0184181.t004
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over-estimating the risk percentage. However, due to the large number of patients analyzed,
this possibility might be ameliorated.
Another weakness, in order to classify patients in a given risk group, is the fact that nearly
60% of patients had an unknown HER2 status, in consequence, a substantial number of
patients, could not be evaluated regarding the TN phenotype, one of the major risk factors for
hereditary breast cancer. Within the time-frame of data collection (patients diagnosed from
1998 to 2001), although the role of HER2 was well known as a prognostic factor, the determi-
nation of this biomarker was not widely used, given that appropriate targeted therapy was only
available for metastatic patients.
Patients with hereditary cancer risk features have worse pathological risk factors, according
to T and N status, and to histological grade, all well-known bad prognosis factors. Data of
prognosis from patients with known BRCA 1 and 2 mutations are conflicting in literature. A
recent meta-analysis did not detect differences in breast cancer specific survival rate in BRCA2
mutation carriers when compared to sporadic ones [16]. I contrast, another meta-analysis con-
fers a poorer prognosis for patients with BRCA1 mutations [17]. Another recent meta-analysis
confer worse overall survival to BRCA1 mutation carriers and worse breast cancer specific sur-
vival [18]. In our study, we did not analyze survival, and we did not have data regarding
BRCA1 and 2 status, so in consequence we cannot put our data into the context of theses
meta-analysis.
One could think that patients concerned with their familial background are more prone to
intensive surveillance, both by themselves and by their health care givers, what should be trans-
lated into earlier diagnostic presentations, something that is not reflected by our data. This is
true in other familial cancers, such as melanoma, where patients at familial risk in Spain pres-
ent with better prognosis pathological factors [13]. However, since the subgroup responsible
for these differences is the individual risk group, which is enriched with the triple negative
phenotype, the known biological aggressiveness of this subtype may account for these differ-
ences in TNM presentation.
It is important to analyze if our data are comparable to other countries. Our results are
according to what is described in general literature [6]. However, studies conducted in other
countries searching for similar endpoints as our present work, revealed mixed results. In a
British study with more than 5,000 BC patients, a positive family history of BC (with no more
specific details) was found in 22.2%, in contrast to 16.8% (14.5% FR and 2.3% IFR groups)
found in our work [19]. In this study, a younger age of presentation was found among patients
with family history. In a pooled analysis with more than 47,000 BC patients, in which 92%
were of European ancestry, revealed that 11% of patients were<40y, 20% had a positive first
degree family history and that 14% were TNBC. 18% of patients with TNBC had also a positive
family history of cancer [20]. In African-American women, a study found that 16% of BC
patients had first degree family history, 3% ovarian cancer and 15% were TNBC [21]. Finally,
in Chinese population, a lower proportion of BC with family history (5.1%) was described in a
study focused in Han Chinese population, the majority of Chinese population ethnicity [22].
These results reveal that family history and other risk factors associated with increased heredi-
tary risk could be dependent of geographical origin, although the limitations of the heteroge-
neity of the different studies should be taken into account.
Finally, the practical consequences of our findings should be taken into consideration. In
general, it is estimated that, according to different institutional series in Spain and western
countries, BRCA 1 or 2 mutations are present from 7% to 20% of selected and unselected
patients in western countries [23–27]. With this in mind, and since genetic testing will be eas-
ier and cheaper in the near future, our findings suggests that it is urgently needed an increase
Familial breast cancer in Spain
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in efforts to facilitate the detection and proper management of patients and relatives harboring
genetic mutations and/or high familial risk features.
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Lescure, Teresa Ramón y Cajal, Gemma Llort, Carlos Jara, Eva Carrasco, Sara López-
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